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Objectives: To investigate the protective effects and mechanism of antioxidant TBHQ
on renal damage caused by doxorubicin chemotherapy in mice with hepatic cancer.
Methods: Cell H22 of mice with hepatic cancer which was subcultured for three times
was subcutaneously transplanted to the groin of right lower limb of 45 SPF Kunming
mice to establish the transplanted tumor model. The doxorubicin chemotherapy group and
antioxidant intervention group received intraperitoneal injection of ADM (1 mg/
kg$0.2 mL/2 d). The model control group received normal saline (NS) of the same
volume at the same time. 1% TBHQ was added into the diet of mice of the antioxidant
intervention group. Seven weeks later, morning urines and peripheral blood were
randomly collected to detect UAlb, UCr, BUN, Scr and UAlb/Cr levels. All mice were
beheaded. The renal tissues were made into homogenate, and SOD, T-AOC and MDA
content in tissues were detected followed by cell lysis. All data were processed using
SPSS19.0.
Results: The UAlb/Cr, BUN, Scr and MDA of doxorubicin chemotherapy group were
signiﬁcantly higher those of model control group and the activities of SOD, T-AOC in
doxorubicin chemotherapy group were lower than those of model control group
(P < 0.01). The UAlb/Cr, BUN, Scr and MDA of antioxidant intervention group were
lower than those of doxorubicin chemotherapy group and the activities of SOD, T-AOC
of antioxidant intervention group were higher than those of doxorubicin chemotherapy
group doxorubicin chemotherapy group (P < 0.05). The BUN of model control group
was higher than that of blank group, and T-AOC was lower than that of blank group, and
difference was statistically signiﬁcant (P < 0.05).
Conclusions: Doxorubicin chemotherapy could lead to abnormal antioxidant capacity
and renal function of tumor-bearing mice with hepatic cancer. TBHQ antioxidant inter-
vention could effectively improve the antioxidant capacity of renal tissue and reduce the
renal damage caused by doxorubicin to some extent.1. Introduction
Liver cancer, with mortality rate ranging from 20 per 100000
to 30 per 100000 in China, is one of the common malignanttumors in digestive system, only second to lung cancer among
malignant tumors [1]. Doxorubicin chemotherapy serves as one
of the routines in treating liver cancer clinically. Doxorubicin,
killing cancer cells via inhibiting the replication of RNA and
DNA to play its anti-tumor effect, is widely used as chemo-
therapeutics in the treatment of malignant tumors, such as liver
cancer, breast cancer, ovarian cancer, gastric cancer, non-small
cell lung cancer, prostate cancer, etc. [2–7]. However, the
severe toxic and side effects of doxorubicin on human body
have restricted its clinical application. Researches have shown
that doxorubicin chemotherapy could generate severe tissue
injury in heart and kidney [8,9], and the symptoms of renalrticle under the CC BY-NC-ND license (http://
Table 1
Comparisons of renal function indexes of mice among groups.
Group BUN (mmol/L) Scr (mmol/L) UAlb/Cr
(mg/mmol)
Blank group 9.86 ± 2.37 65.21 ± 5.98 1.74 ± 0.21
Model control
group
10.21 ± 2.95b 67.85 ± 6.13 1.81 ± 0.35
Doxorubicin
chemotherapy
group
21.36 ± 5.32** 91.65 ± 10.35** 5.62 ± 0.93**
Antioxidant
intervention
group
15.21 ± 3.64**a 76.32 ± 8.64*a 2.42 ± 0.45*a
*P < 0.05 compared with model control group; **P < 0.01 for the
comparisons with model control group, Statistically signiﬁcant
difference.
a Compared with doxorubicin chemotherapy group. b Compared with
blank group.
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Therefore, seeking clinical treatment to lower the side effects of
doxorubicin chemotherapy and protect renal damage has been
one of the priorities in recent researches.
One of the mechanisms of renal tissue injury caused by
doxorubicin was the free radical it produced could cause lipid
peroxidation of glomerulus which affected normal physiological
function of renal tissues, thus generating metabolic disorders
[10,11]. Therefore, one of the methods to reduce renal damage is
to inhibit peroxidation. Tertiary butylhydroquinone (TBHQ) is a
edible antioxidant with a safer non-toxic property compared with
other antioxidants. Studies have indicated that the protective
effect of TBHQ was realized through inhibition of peroxidatic
reaction, inﬂammatory response and apoptosis [12]; however, the
researches concerning its clinical applications are still immature.
To provide theoretical reference and experimental bases for new
type adjuvant chemotherapy, the study explored the effects of
TBHQ prevention on renal damage caused by doxorubicin
chemotherapy through establishing transplanted tumor model
of H22 mice with hepatic cancer and conducting the
experiments of doxorubicin chemotherapy and antioxidant
prevention.
2. Materials and methods
2.1. Materials
A total of 60 SPF Kunming mice (half male and half female),
aged 6–8 weeks and weighed 18–23 g, were purchased from the
Laboratory Animal Center, Zhengzhou University. The study
was performed after one-week adaptive feeding and the room
temperature of feeding environment was kept between 21 C and
25 C and relative humidity between 35% and 50%. Hepatoma
cell line H22 of abdominally transplanted mice was purchased
from Shanghai Hanbo Biotechnology Co., Ltd., doxorubicin
from Melone Pharmaceutical Co., Ltd., TBHQ, SOD, and
xanthine oxidase from Sigma Co., T-AOC kit from Nanjing
Jiancheng Bioengineering Institute. Beckmann fully automatic
biochemical analyser (AU5821 version) was used as experi-
mental instrument.
2.2. Methods
Cryopreserved cell H22 was transplanted into abdominal
cavity of mice after thawing with 37 C aqueous bath. After 5–7
days, substantial ﬂuids were developed in the abdominal cavity.
Cell H22 was subcultured for three times before collecting
abdominal dropsy of hepatoma mice, which was diluted into cell
suspension under the microscope with a cell population of (1.0–
1.5) × 107 per mL. 0.2 mL cell suspension from each mouse
among 45 randomly selected mice was subcutaneously trans-
planted to the groin of right lower limb. The tumor block grown
subcutaneously after 1–2 days was regarded as a successful
modeling.
Forty-eight hours after modeling, 45 tumor-bearing mice were
randomly divided into three groups: model control group,
doxorubicin chemotherapy group and antioxidant intervention
group, with 15 mice in each group. The doxorubicin chemo-
therapy group and antioxidant intervention group received
intraperitoneal injection of ADM (1 mg/kg$0.2 mL/2 d); the
model control group received intraperitoneal injection of normalsaline (NS) of the same volume at the same time. 1% TBHQ was
added into the diet of mice of antioxidant intervention group. A
total of 15 normal mice served as blank group. Seven weeks later,
urines in the morning and peripheral blood (supernatant was
collected after plasma centrifugation) were randomly collected
and UAlb, UCr, BUN, Scr and UAlb/Cr were detected after-
wards. All mice were beheaded. The renal tissues were made into
homogenate, and SOD, T-AOC and MDA content in tissues were
detected followed by cell lysis. MDA was detected using TBA,
other indicators were operated in strict accordance with kit in-
structions. All data were processed using SPSS19.0 and
demonstrated as x ±s. T-test was conducted between two data
sets, and difference was statistically signiﬁcant when P < 0.05.
All experiments in this study are conducted in accordance
with animal healthcare and user guide of Laboratory Animal
Center of Zhengzhou University, Henan province and under the
approval of local ethics committee, meeting criteria for labora-
tory animal care and application guidelines of US National In-
stitutes of Health (Publication. 85-23, revised in 1985).
3. Results
Renal function indexes (BUN, Scr and UAlb/Cr) in mice of
each group were shown in Table 1. BUN in model control group
increased compared to blank group and the difference is sig-
niﬁcant, differences in other indexes showed no difference.
BUN, Scr and UAlb/Cr of tumor-bearing mice underwent
doxorubicin chemotherapy elevated signiﬁcantly, indicating that
doxorubicin chemotherapy would damage renal function. These
indexes in mice receiving antioxidant intervention all decreased,
indicating that antioxidant intervention to some extent could
protect renal damage in mice with heptic cancer.
Oxide and antioxidant indexes (SOD, T-AOC and MDA) in
mice of each group were shown in Table 2. As shown in Table 2,
T-AOC in model control group reduced compared to blank
group showing signiﬁcant difference. The activity of SOD and
T-AOC of tumor-bearing mice receiving doxorubicin chemo-
therapy declined while MDA content increased, demonstrating
that doxorubicin chemotherapy would lower antioxidant capac-
ity of mice and strengthen peroxidatic reaction. The activity of
SOD and T-AOC increased after antioxidant intervention during
chemotherapy and MDA content decreased or even reached to
Table 2
Comparisons of oxide and antioxidant indexes of mice among groups.
Group SOD (U/mL) T-AOC (U/mL) MDA (nmol/g)
Blank group 216.52 ± 19.22 12.61 ± 4.13 4.98 ± 1.27
Model control
group
212.61 ± 20.54 10.82 ± 3.56b 5.41 ± 1.68
Doxorubicin
chemotherapy
group
148.63 ± 12.35** 6.39 ± 2.16** 7.69 ± 2.12**
Antioxidant
intervention
group
186.76 ± 17.62**a 9.24 ± 2.85*a 6.13 ± 2.01a
*P < 0.05 compared with model control group, statistical difference;
**P < 0.01 compared with model control group.
a Compared with doxorubicin chemotherapy group. b Compared with
blank group.
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effectively improve antioxidant capacity and reduce peroxidatic
reaction.
4. Discussion
Peroxidatic reaction was considered as one of the primary
mechanisms of renal damage caused by doxorubicin chemo-
therapy [13]. In this study, transplanted tumor model of H22 mice
with hepatic cancer was established, doxorubicin chemotherapy
plus TBHQ prevention were conducted, antioxidant capacity
indexes and renal function indexes were measured after
treatment and prevention and the protective effect and
mechanism of TBHQ prevention on renal damage caused by
doxorubicin chemotherapy were explored. Results showed that
BUN, Scr and UAlb/Cr in mice after receiving doxorubicin
chemotherapy increased, with renal function damage present;
the activity of T-AOC and SOD declined, MDA content
elevated, antioxidant capacity decreased, Peroxidatic reaction
strengthened. BUN, Scr and UAlb/Cr in mice underwent
doxorubicin chemotherapy combined with TBHQ antioxidant
intervention were lower than those of doxorubicin
chemotherapy group, while antioxidant capacity and SOD
activity were higher, indicating antioxidant capacity of tumor-
bearing mice was improved and its renal damage was pro-
tected to some degree.
The mechanisms of renal damage caused by doxorubicin
chemotherapy mainly consists of two aspects: one is direct
damage. The general toxicity of doxorubicin on cells directly
damaged renal cells, which produced inﬂammatory response in
renal tissues and released such inﬂammatory factors as TNF-a
and interleukin, hence strengthening the growth of renal matrix
and glomerular sclerosis [14]. The other is indirect damage. Under
the action of multiple reductase, doxorubicin produced free
radical, induced lipid peroxidation in glomerular epithelial cell
and caused abnormal glucose and protein metabolism;
moreover, it brought about elevated urinary albumin through
altering and breaking the structure and ﬁlterability of renal
ﬁltration membrane [15,16]. Most researches come to the
conclusion that indirect damage predominates. Irregular
glomerular epithelial cell, inﬂammatory response in renal
matrix and nephrotic syndrome (urine protein, hematuresis,
etc.) were present followed by renal damage which was caused
by doxorubicin, according to the study of Carron PL et al. [17].THBQ, as an antioxidant, is frequently used in the food
industry. Researches had shown that TBHQ could activate
Nrf2 and then activate the expressions of its mediated NQO1
and SOD before playing a protective role in cellular
antioxidant reaction and inhibiting peroxidatic reaction, which
played a part in tissue protection under the conditions of heart
toxic damage, renal damage, stroke, brain trauma [18,19].
Therefore, it can be inferred that TBHQ inhibits lipid
peroxidation as well as enhances antioxidant capacity of renal
cells via activating the expressions of Nrf2 mediated SOD, thus
reducing renal damage caused by doxorubicin chemotherapy to
some degree. The application of TBHQ antioxidant in clinic
and medicine at present are still immature, however, with
gradually carried out researches and increasingly progress,
solving this medical challenge can be expected soon.
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